Review Article

Imaging of the thyroid: Recent advances

Vikas Chaudhary, Shahina Bano

Department of Radiodiagnosis, Employees’ State Insurance Corporation (ESIC) Model Hospital, Gurgaon-122001, Haryana, Department of Radiodiagnosis, Lady Hardinge Medical College and Associated Smt. Sucheta Kriplani and Kalawati Hospitals, New Delhi, India

ABSTRACT

Although thyroid scintigraphy and ultrasound continues to be the mainstay of the diagnostic imaging of the thyroid gland, there have been several recent advances that are of interest to both radiologists and endocrinologists. In this review article, the authors discuss recent progress in imaging of the thyroid by use of radionuclide imaging including single photon-emission computed tomography/positron emission tomography, ultrasonography (USG), USG elastography, computed tomography (CT), magnetic resonance imaging (MRI), and optical coherence tomography.

Key words: Magnetic resonance imaging, optical coherence tomography, radionuclide imaging, thyroid imaging, recent advances, ultrasonography, ultrasound elastography, computed tomography

INTRODUCTION

The thyroid gland plays a critical role in regulating metabolic functions including heart rate and cardiac output, lipid metabolism, heat regulation, and skeletal growth. Recent advances in thyroid imaging have considerably improved the diagnosis, treatment, follow-up, and prognosis of high prevalence thyroid diseases such as thyroid nodule, goiter, thyroiditis, and thyroid cancer that affect the normal thyroid function. The relative roles of various imaging modalities in the evaluation of various thyroid diseases are discussed here.

TECHNIQUES OF THYROID IMAGING

Radionuclide imaging

Radionuclide imaging (RNI) has been a part of the thyroid evaluation for many years. Now, it plays a central role in the evaluation of thyroid disease as it provides excellent functional information about the thyroid gland. The most frequently used isotopes for thyroid scintigraphy are $^{99m}$Technetium pertechnetate, $^{131}$Iodine, $^{18}$fluoro-deoxyglucose, and gallium-67. Radionuclide scanning using $^{99m}$Technetium pertechnetate and $^{131}$Iodine is used in the evaluation of focal thyroid nodule as hot, warm, or cold on the basis of relative uptake of radioactive isotope by the nodule [Figures 1–4]. $^{131}$Iodine, in addition, is also used in the treatment of patients with thyroid cancer to evaluate for residual/recurrent disease, to assess distant metastasis, and in the follow-up of patients after thyroidectomy. Gallium-67 is particularly useful in assessing thyroid lymphoma.

Positron emission tomography

Two new radionuclide techniques, namely positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are of potential interest in imaging of the thyroid.

F18-fluorodeoxyglucose-PET ($^{18}$F-FDG-PET) is a well established imaging modality in oncology. Its greatest utility is in the evaluation of thyroid cancers with dedifferentiated tumors which are iodine scintigraphy negative but FDG-PET positive (in contrast to indolent slow growing thyroid tumors which are iodine scintigraphy positive but FDG-PET negative). $^{18}$F-FDG-PET has been found...
to be the most accurate method for detecting recurrent or metastatic medullary thyroid carcinoma (MTC) in patients with an elevated calcitonin level (tumor marker for MTC) postoperatively, when other radionuclide and cross-sectional imaging techniques fail to localize the tumor or metastatic disease. It is also superior to other imaging modalities in localizing cervical and mediastinal lymph node involvement.\(^{[5,7]}\)

The combination of PET with CT or MRI (PET/CT or PET/MRI) which allows fusion of functional and anatomic information has a very promising role in the evaluation of thyroid cancer. The sensitivity and specificity of FDG PET-CT to detect the suspected occult lesions and residual/recurrent well-differentiated thyroid cancer (DTC) is very high.

Currently, whole-body FDG PET-CT is recommended for assessing the metastases of DTC in patients with radioiodine negative scans and elevated serum thyroglobulin (Tg) levels. This is particularly useful in guiding treatment decisions.\(^{[8,9]}\) FDG PET is also useful in differentiating incidentaloma (show focal uptake of FDG by the gland) from thyroiditis and/or hypothyroidism (show diffuse uptake of FDG by the gland); and malignant thyroid nodule (show high FDG avidity, approaching 100%) from benign nodule (show low FDG avidity, \(\sim 30\%)\(^{[3,10,11]}\).
Single photon emission computed tomography
SPECT is currently used with increased frequency due to its ability to provide the three-dimensional information which improves the overall sensitivity for detection and localization of a thyroid lesion. $^{131}$I SPECT-CT has been found to be more accurate than FDG PET-CT in localizing the regional and distant metastasis and in detecting residual/recurrent disease in the case of well-differentiated thyroid cancer. The most important advantage of fusion FDG PET-CT and $^{131}$I SPECT-CT is detection of metastasis in normal sized lymph nodes.$^{[9]}$

The major drawback of FDG-PET is its poor specificity to differentiate between infective or inflammatory processes and the neoplasm, as well as its poor sensitivity to detect micrometastases and tumor sites in well-differentiated thyroid cancers that concentrate iodine. The major drawback with $^{131}$I SPECT is that various physiological variants may mimic disease.$^{[9]}$

Ultrasonography
Ultrasonography is generally the first choice and the most sensitive imaging modality for diagnosing intrathyroid lesions. Because of its superficial location, the thyroid gland is ideally suited for high-frequency sonography (using 7-13 MHz transducer) which facilitates the detection of clinically non-palpable nodules of 2-3 mm size and allows a more accurate morphological characterization of the lesion. It is also used to determine the size and number of thyroid nodules, to assess the volume of thyroid tissue in cases of thyromegaly, and to differentiate thyroid masses from adjacent non-thyroid masses.

Addition of color and spectral Doppler imaging that determines the vascular pattern of thyroid diseases has been found to be very useful tool in screening the thyroid nodule for malignancy. A nodule with exclusively central vascular pattern is characterized as malignant, while a nodule with a predominantly perinodular pattern is generally benign. The gray scale ultrasonographic pattern associated with thyroid carcinoma includes a solid, hypoechoic mass that is taller than wide, has an irregular margin and microcalcifications but absent halo sign. The improved gray scale and Doppler sonography has increased the accuracy and specificity of ultrasound for thyroid diseases figures 5-8. This combination is also helpful in evaluation of cervical lymphadenopathy. Metastatic lymph nodes appear hypoechoic and show lack of central hilar echogenicity and vascularity.$^{[3,12-15]}$

Ultrasound elastography
Ultrasound (US) elastography measures the tissue elasticity and differentiates between benign and malignant nodule on the basis of consistency of the lesion. A benign nodule is softer and hence deforms more easily, whereas the malignant nodule is harder and hence deforms less when compressed by ultrasound probe. Cystic nodules and nodules having calcified shell are excluded from the US elastographic evaluation. US elastography has a high predictive value in characterizing an indeterminate nodule as malignant with its effectiveness almost comparable to fine-needle aspiration cytology (FNAC)$^{[13,15-17]}$

Other improvements in ultrasonography
Use of specific contrast (e.g. SonoVue) and pulse inversion harmonic imaging has further improved the efficacy of ultrasound to characterize a thyroid nodule.$^{[18]}$ Ultrasonography-guided fine needle aspiration biopsy (FNAB) is particularly helpful in the case of nonpalpable or small nodules or the nodules that are difficult to access and is preferable to palpation-guided FNAB by many pathologists for appropriate nodule selection.$^{[19]}$

Main limitation with use of USG is a significant overlap between benign and malignant thyroid nodules; hence, FNAB is necessary in many cases with equivocal findings.$^{[19]}$ US elastography also has limitation in assessing lesions that are not surrounded by adequate normal tissue.$^{[15]}$

Computed tomography and magnetic resonance imaging
Computed tomography (CT) and magnetic resonance imaging (MRI) have an adjuvant role in the evaluation of thyroid disease. CT and MRI are less sensitive than USG in detecting and characterizing intrathyroid lesions as benign and malignant. They are particularly used for staging thyroid cancer as they are useful in evaluating regional lymphadenopathy, assessing loco-regional extension of the tumor (particularly involving trachea and esophagus), spread of disease into the mediastinum or retrotracheal region and detecting pulmonary and hepatic metastases. CT and MR imaging are also recommended to evaluate the occult metastases (mediastinal or retropharyngeal) in post-thyroidectomy follow-up cases with elevated serum Tg level and negative sonographic finding.$^{[1,20,21]}$

CT, in particular, is most sensitive in detecting intraglandular calcification[figure 9]. Fusion PET-CT and PET-MRI play a promising role in the evaluation of thyroid cancer.$^{[9]}$ Diffusion-weighted imaging (DWI) may be helpful in differentiating benign and malignant nodules. Benign nodules have higher apparent diffusion coefficient (ADC) values than malignant ones.$^{[20]}$ MR spectroscopy using long echo-time (TE) has been proved to be a sensitive method in differentiating thyroid carcinoma from benign follicular lesion. Choline peak is identified in almost all carcinomas, with raised choline/creatinine ratio ranging from 1.6 in well
differentiated carcinoma to 9.4 in anaplastic carcinoma. The normal thyroid tissue and benign follicular lesions generally demonstrate no choline peak.[23]

**Optical coherence tomography and optical coherence microscopy**

Optical coherence tomography (OCT) and optical coherence microscopy (OCM) are emerging imaging technologies based on inherent optical contrast. OCT provides high-resolution, real-time, cross-sectional imaging of tissues. OCM is an extension of OCT and provides high magnification resulting in cellular imaging. OCT/OCM system uses infrared light in fiber active device that allows visualization of microstructures of gland (1-15 µm cellular range) and provides high resolution images comparable with those obtained using histopathologic methods. OCT and OCM can clearly differentiate between benign and malignant thyroid tissue using intrinsic optical contrast.[24,25]

**Conclusion**

In general, the thyroid imaging has evolved from early
radionuclide thyroid scanning to the development of the advanced technique of SPECT, PET and fusion imaging. The advancement in cross-sectional techniques such as USG, CT and MRI has further improved the evaluation of intrathyroid pathologies. OCT has supplemented the imaging for better selection of patients for operation.

**Acknowledgement**

The authors would like to thank Dr. Deepa Prajapati for providing Tc-99m scintigraphy images. We also thank Dr. Deepti Jain for the unconditional support.

**References**

1. Hopkins CR, Reading CC. Thyroid and parathyroid imaging. Semin Ultrasound CT MR 1995;16:279-95.
2. Gates JD, Benavides LC, Shriver CD, Peoples GE, Stoianovic A. Preoperative thyroid ultrasound in all patients undergoing parathyroidectomy?. J Surg Res 2009;155:254-60.
3. Soto GD, Halperin I, Squarcia M, Lomena F, Domingo MP. Update in thyroid imaging: The expanding world of thyroid imaging and its translation to clinical practice. Hormones (Athens) 2010;9:287-98.
4. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.
5. Ersöz R, Karako A, Atasever T. Imaging techniques for metastatic thyroid medullary cancer. Turk J Endocrinol Metabol 2002;4:149-53.
6. Reading CC, Gorman CA. Thyroid imaging techniques. Clin Lab Med 1993;13:711-24.
7. Heshmati HM, Gharib H, Van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med 1997;103:60-9.
8. Zoller M, Kohlihurst S, Igerc I, Kresnik E, Galloetsch HJ, Gomez I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: What is the impact of each modality?. Eur J Nucl Med Mol Imaging 2007;34:487-95.
9. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br J Radiol 2009;82:860-76.
10. Van den Brul A, Maes A, De Potter T, Mortelmans L, Drijkoningen M, Van DB, et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 2002;87:1517-20.
11. De Geus-Oei LF, Pieters GF, Bonenkamp JJ, Mucke AH, Bleeker-Rovers CP, Corstens FH, et al. 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med 2006;47:770-5.
12. Gooding GA. Sonography of the thyroid and parathyroid. Radiol Clin North Am 1993;31:967-89.
13. Kerr L. High resolution thyroid ultrasound: The value of color doppler. Ultrasound Q 1994;12:21-43.
14. Hoang JK, Lee WK, Lee M, Johnson D, Farrell S. US Features of thyroid malignancy: Pearls and pitfalls. Radiographics 2007;27:847-65.
15. Rago T, Vitti P. Role of thyroid ultrasound in the diagnostic evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008;22:913-28.
16. Rago T, Santini F, Scutari M, Pinchera A, Vitti P. Elastography: New developments in ultrasound for predicting malignancy in thyroid nodules. J Clin Endocrinol Metab 2007;92:2917-22.
17. Lyschik A, Hijishi T, Asato R, Tanaka S, Ito J, Mai JJ, et al. Thyroid gland tumor diagnosis at US elastography. Radiology 2005;237:202-11.
18. Bartolotta TV, Midiri M, Quaia E, Bertolotto M, Galia M, Cademartiri F, et al. Benign focal liver lesions: Spectrum of findings on SonoVue enhanced pulse-inversion ultrasonography. Eur Radiol 2005;15:1643-9.
19. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005;237:794-800.
20. Imanishi Y, Eghara N, Mori J, Shimokawa M, Sakuyama K, Ishikawa T, et al. Measurement of thyroid iodine by CT. J Comput Assist Tomogr 1991;15:287-90.
21. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
22. Bozgeyik Z, Coskun S, Dagli AF, Oral Y, Sahbaz F, Oğur E. Diffusion-weighted MR imaging of thyroid nodules. Neuroradiology 2009;51:193-8.
23. King AD, Yeung DK, Ahuja AT, Tse GM, Chan AB, Lam SS, et al. In vivo 1H MR spectroscopy of thyroid carcinoma. Eur J Radiol 2005;54:112-7.
24. Zhou C, Wang Y, Aguirre AD, Tsai TH, Cohen DW, Connolly JL. Ex vivo imaging of human thyroid pathology using integrated optical coherence tomography and optical coherence microscopy. J Biomed Opt 2010;15:016001.

25. Pantanowitz L, Hsiung PL, Ko TH, Schneider K, Herz PR, Fujimoto JG, et al. High-resolution imaging of the thyroid gland using optical coherence tomography. Head Neck 2004;26:425-34.